Approved Targeted Oncology Drugs

The current standard of care is anchored by several highly successful biotherapeutics that have validated the commercial and clinical viability of complex biologics.

Blockbuster Antibody-Drug Conjugates (ADCs)

ADCs have firmly established themselves as critical Targeted Oncology Drugs in breast cancer and solid tumors:

  • Enhertu (trastuzumab deruxtecan): Developed by AstraZeneca and Daiichi Sankyo, Enhertu revolutionized the treatment of HER2-low and HER2-positive breast cancers, generating over $2.3 billion in global sales in 2023.
  • Trodelvy (sacituzumab govitecan): Utilizing a topoisomerase payload directed at TROP2, this Gilead Sciences therapy has achieved significant survival benefits in metastatic triple-negative breast cancer (TNBC).
  • Kadcyla, Adcetris, and Mylotarg: These legacy approvals remain cornerstone therapies across HER2-positive breast cancer and various hematologic malignancies.

Commercialized Bispecific Antibodies

Bispecific antibodies, which can simultaneously engage two distinct targets, have secured major regulatory approvals:

  • Talvey (talquetamab) & teclistamab: In multiple myeloma, these T-cell engagers have demonstrated remarkable response rates by bridging T-cells to GPRC5D and BCMA.
  • Columvi (glofitamab): Provides a critical off-the-shelf, fixed-duration treatment option for diffuse large B-cell lymphoma (DLBCL).
  • Rybrevant (amivantamab): Acts as a highly effective dual EGFR and MET inhibitor for NSCLC patients with EGFR exon 20 insertion mutations.

Clinical-Stage Targeted Oncology Drugs

The biopharma pipeline is rapidly expanding beyond monospecific targets. The next wave of Targeted Oncology Drugs focuses on bispecific ADCs and dual-payload architectures designed to overcome resistance and combat tumor heterogeneity.

Next-Generation Bispecific ADCs

Several high-profile programs are actively advancing through clinical evaluation in 2026:

Advanced Bispecifics and Small Molecules

Beyond ADCs, other Targeted Oncology Drugs are showing profound clinical promise. Pumitamig (BNT327), an Fc-silenced PD-L1/VEGF bispecific co-developed by BioNTech and Bristol Myers Squibb, is acting as a next-generation immuno-oncology backbone in late-stage trials. Meanwhile, ArriVent BioPharma’s firmonertinib, a highly brain-penetrant tyrosine kinase inhibitor (TKI), is advancing through global Phase 3 trials for uncommon EGFR variants.

Pipeline Summary

Drug Candidate Modality Target(s) Current Status
Enhertu Monospecific ADC HER2 Approved / Marketed
JSKN027 Bispecific ADC PD-L1 / VEGFR2 Phase 1 Dosed
NEOK001 Bispecific ADC B7-H3 / ROR1 Phase 1 IND Cleared
Firmonertinib Tyrosine Kinase Inhibitor EGFR (Uncommon) Phase 3 Ongoing

References


Leave a Reply

Your email address will not be published. Required fields are marked *